Last reviewed 2026-04-22 · How we verify

DMX-200

DMX-200 is a dual VEGF and Ang2 inhibitor that blocks angiogenesis and vascular destabilization to reduce tumor blood supply and improve vascular function.

DMX-200 is a dual VEGF and Ang2 inhibitor that blocks angiogenesis and vascular destabilization to reduce tumor blood supply and improve vascular function. Used for Diabetic kidney disease, Diabetic retinopathy.

At a glance

Mechanism of action

DMX-200 simultaneously inhibits vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) signaling pathways. By targeting both pathways, it aims to normalize tumor vasculature and reduce pathological angiogenesis more effectively than single-target agents. This dual mechanism may improve drug delivery to tumors and reduce resistance development.

Approved indications

• Diabetic kidney disease
• Diabetic retinopathy

Common side effects

• Hypertension
• Proteinuria
• Anemia
• Fatigue

Key clinical trials

• A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (PHASE3)
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
• Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 (PHASE2)
• Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan (PHASE2)
• Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.